Correlation between human papillomavirus type 16 infection and human leukocyte antigen class I expression in cervical cancers of Uighur women

Chinese Journal of Pathology

Volumn 39, Issue 4, 2010, Pages 255-258

  Ma, Qi ^a   Hasim, Ayshamgul ^b   Abudukadeer, Abida ^b   Yilike, Xiamixinuer ^b   Wu, Gui Zhen ^b   Abudula, Abulia ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

HLA antigens; Human papillomavirus 16; Uterine cervical neoplasms

Indexed keywords

HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; MESSENGER RNA;

ADULT; AGED; ARTICLE; CHINA; ETHNOLOGY; FEMALE; GENETICS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; PAPILLOMAVIRUS INFECTION; SQUAMOUS CELL CARCINOMA; UTERINE CERVICITIS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VIROLOGY;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHINA; FEMALE; HLA ANTIGENS; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-C ANTIGENS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; RNA, MESSENGER; UTERINE CERVICAL NEOPLASMS; UTERINE CERVICITIS;

EID: 77952654732     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0529-5807.2010.04.010     Document Type: Article

References (15)

1. Yang BH, Bray FI, Paikin DM, et al Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost Int J Cancer, 2004, 109(3): 418-424.
2. Koopman LA, Corver WE, van der Slik AR, et al. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med, 2000, 191(6): 961-976.
3. Chil A, Sikorski M, Bobek M, et al. Alterations in the expression of selected MHC antigens in premalignant lesions and squamous carcinomas of the uterine cervix. Acta Obstet Gynecol Scand, 2003, 82(12): 1146-1152.
4. Monsonego J. HPV infections and cervical cancer prevention. Priorities and new directions. Highlights of EUROGIN 2004 International Expert Meeting, Nice, France, October 21-23, 2004. Gynecol Oncol, 2005, 96(3): 830-839.
5. Garrido F, Ruiz-Cabello F, Cabrera T, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today, 1997, 18(12): 89-95.
6. Paulsson KM. Evolutionary and functional perspectives of the major histocompatibility complex class I antigen-processing machinery. Cell Mol Life Sci, 2004, 61(19-20): 2446-2460.
7. Zhang Y, Williams DB. Assembly of MHC class I molecules within the endoplasmic reticulum. Immunol Res, 2006, 35(1-2): 151-162.
8. Seliger B, Ritz U, Ferrone S. Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer, 2006, 118(1): 129-138.
9. de Boer MA, Jordanova ES, van Poelgeest MI, et al. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts. Int J Cancer, 2007, 121 (12): 2711-2715.
10. Li H, Ou X, Xiong J, et al. HPV16E7 mediates HADC chromatin repression and downregulation of MHC class I genes in HPY16 tumorigenic cells through interaction with an MHC class I promoter. Biochem Biophys Res Commun, 2006, 349(4): 1315-1321.
11. Ashrafi GH, Haghshenas M, Marchetti B, et al E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int J Cancer, 2006, 119(9): 2105-2112.